AstraZeneca PLC (NASDAQ: AZN)'s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in ...

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

The strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca also has a profit-sharing deal with ...

AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...